Prospects for a MERS-CoV spike vaccine
Introduction: Six years have passed since Middle East respiratory syndrome (MERS) coronavirus (MERS-CoV), a newly emerging infectious virus, was first reported in 2012. Although MERS-CoV has had a consistently high mortality rate in humans, no vaccines have been approved to prevent MERS-CoV infectio...
Saved in:
Main Authors: | Yusen Zhou (Author), Shibo Jiang (Author), Lanying Du (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2018-08-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
MERS-CoV
by: Du, Lanying
Published: (2019) -
Receptor-binding domain of MERS-CoV with optimal immunogen dosage and immunization interval protects human transgenic mice from MERS-CoV infection
by: Yufei Wang, et al.
Published: (2017) -
Genetic diversity of MERS-CoV spike protein gene in Saudi Arabia
by: Sayed S. Sohrab, et al.
Published: (2020) -
The latest advancements in Zika virus vaccine development
by: Lanying Du, et al.
Published: (2017) -
Characterization and immunogenicity assessment of MERS-CoV pre-fusion spike trimeric oligomers as vaccine immunogen
by: Rahul Ahuja, et al.
Published: (2024)